A novel conditioning regimen using helical tomotherapy (HT) was developed to deliver 10 Gy for total body irradiation (TBI) and simultaneously augment dose to 12 Gy for targeted dose boost to total marrow, central nervous system leukemia, and extramedullary disease sites in patients with high-risk or relapsed/refractory acute lymphoblastic leukemia (ALL) receiving haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT). Fourteen patients were included, eight of these patients were in first complete remission (CR1), one was in CR2, one had a partial response and four patients had refractory disease at transplantation. The median delivered average dose was 11.395 Gy (range 10.06-12.17). The median planning target volume D95 was 8.2 Gy (range 7.52-9.01). The median delivered dose to skeleton bone with active bone marrow sites was 12.685 Gy (range 11.12-13.52). The results of this trial suggest that using HT TBI confers satisfactory immunosuppression and excellent eradication of malignant cells in patients with high-risk ALL undergoing allo-HSCT, especially in those with refractory ALL. After a median follow-up of 14.6 months (range 4-28), four patients experienced non-relapse mortality, ten patients are alive in durable CR including remission of extramedullary leukemic infiltration. One-year overall survival and disease-free survival rates post-transplantation were both 70.7%.
Introduction
The outcome of patients with high-risk acute lymphoblastic leukemia (ALL) is dismal. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a better chance of a cure in patients with high-risk or relapsed/refractory disease. Although transplant-related mortality (TRM) has been significantly decreased in the past decades, relapse is high after HSCT for ALL. Relapse rates in children with highrisk ALL undergoing allo-HSCT are 25-40% [1] . Developing strategies to further decrease relapse and improve survival are vital. Total body irradiation (TBI) has been established as a standard part of the conditioning regimen in patients with ALL undergoing allo-HSCT. TBI contributes to the eradication of malignant cells, especially those in sanctuary sites not easily reached by chemotherapy drugs and chemotherapy-resistant cell clones. The other purpose of TBI is immunosuppression by dampening the host immune response to allow healthy donor cell engraftment. With regards to the influence of TBI on the risk of graft-versushost disease (GVHD), although previous comparative studies did not observe a higher incidence of GVHD using TBI-based conditioning regimens compared with oral busulfan (Bu)-based regimens [2] [3] [4] , the majority of recently published studies have demonstrated TBI-based Zujun Jiang and Junsong Jia contributed equally to this work.
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jdxiao111@163.com * Haowen Xiao haowenxiao1974@hotmail.com conditioning regimens to cause more GVHD than intravenous Bu, likely due to greater tissue injury and release of inflammatory cytokines [5] [6] [7] [8] .
Although the higher radiation dose resulted in the reduced risk of leukemia relapse, it also increased the risk of TRM due to the lack of precision in classic TBI and the sensitivity of vital organs. To decrease relapse rate post HSCT, a more targeted form of TBI is clearly needed to allow for further dose escalation, and reduce the dose to normal organs relative to the tumor. The advent of helical tomotherapy (HT) represents the integration of computed tomography (CT) image-guided beam delivery and intensity-modulated radiotherapy in a single device, that employs a megavoltage (MV) linear accelerator mounted on a CT gantry. This type of device provides a rotating beam source with a multileaf collimator moving in a spiral pattern relative to the patient, which allows large volumes to be delineated and treated, while neighboring volumes may be spared [9] . HT provides the option to deliver a highly conforming radiation dose specifically to the body sites harboring leukemic cells, while simultaneously reducing doses to critical normal organs to avoid severe side effects. Encouraging outcomes have been reported in several small trials of HT to deliver total marrow irradiation (TMI) as a targeted dose boost modality after conventional TBI in patients with hematologic malignancies undergoing auto-HSCT or allo-HSCT [10] [11] [12] . On the other hand, we previously reported that haploidentical-related donor (HRD) HSCT carried a superior graft-versus-leukemia effect compared to matched sibling donor or unrelated donor HSCT in patients with high-risk acute leukemia [13] . In the present study, to gain further improvements in the outcomes of patients with high-risk or relapsed/refractory ALL receiving HRD-HSCT, we developed a novel conditioning regimen using HT to simultaneously deliver TBI and a targeted dose boost to total marrow, central nervous system (CNS) leukemia, and extramedullary disease sites
Patients and methods

Patients
From September 2013 to April 2016, all eligible patients were included in the study. Inclusion criteria were as follows: (1) Diagnosis of high-risk ALL or relapsed/refractory ALL. Patients were classified as high risk if they met one of the following criteria at diagnosis: (i) adverse cytogenetics [t (9;22) or BCR-ABL, MLL translocations, t(17;19), near haploidy or low hypodiploidy, or complex karyotype (>5 abnormalities)]; (ii) age >35 years; (iii) high leukocyte counts (>30 × 10 9 /L for B precursor ALL or >100 × 10 9 /L for T-precursor ALL); (iv) CNS leukemia or extramedullary leukemia at diagnosis; (v) patients in CR2 or beyond [14, 15] . Refractory ALL was defined as primary induction failure, or relapse and refractory to salvage combination chemotherapy. (2) Lack of human leukocyte antigen (HLA)-matched related donor or HLA-matched unrelated donor. (3) No decompensated organ diseases. The institutional review board at Guangzhou General Hospital of Guangzhou Military Command approved the protocol, and all patients or their guardians gave their written informed consent. The protocol was registered at the Chinese Clinical Trial Registry (www.chictr.org) (Identifier: ChiCTR-ONRC-13003474).
Chemotherapy prior to HSCT
Patients received initial induction chemotherapy in accordance with the National Comprehensive Cancer Network Guidelines on ALL, which included VDCLP [vincristine, daunorubicin, cyclophosphamide (Cy), L-asparaginase and prednisone], or VDCP, or VDLP. Consolidation chemotherapy regimens included CAM (Cy, cytosine arabinoside (Ara-c) and mercaptopurine), or high-dose methotrexate (MTX) + L-asparaginase. Patients who did not achieve CR after induction received salvage intensified chemotherapy, which included DAEL [dexamethasone, Ara-c, etoposide, L-asparaginase], or Hyper-CVAD (A) (Cy, doxorubicin, vincristine, and dexamethasone), Hyper-CVAD (B) [MTX and Ara-c]. Prophylaxis of CNS leukemia consisted of intrathecal chemotherapy with MTX, Ara-c and dexamethasone for at least six doses during induction and consolidation chemotherapy.
Transplant procedures
All patients were given a myeloablative conditioning regimen. This regimen consisted of TBI (over days −6 to −4) + Cy (60 mg/kg/d IV on days −3 to −2), and anti-T-lymphocyte globulin (ATG-F, Fresenius, Bad Homburg, Germany) (4 mg/ kg/d IV on days −5 to −1). In conventional TBI-based myeloablative regimens, use of 12 Gy fractional TBI in combination with chemotherapy were most commonly employed [9] . Because of racial disparity in tolerance to toxicity, only 7.7-9 Gy fractional TBI in combination with chemotherapy were routinely used in Chinese population [16] [17] [18] , which may be associated with decreased therapeutic effect. In the present study, the TBI program uses HT to further escalation of myeloablative TBI doses by simultaneously delivering 10 Gy for TBI and 12 Gy for total marrow and extramedullary disease sites including CNS leukemia.
GVHD prophylaxis was administered as described previously [13] . All patients received the same GVHD prophylaxis, consisting of cyclosporin A (CSA), MTX and low-dose mycophenolate mofetil (MMF). CSA was scheduled to be given intravenously at 2.5 mg/kg/day from day -7, with a target blood level of 200-300 ng/mL. According to chimeric status, evidence of GVHD and patient's tolerance, CSA was switched to oral formulation during the second month post transplantation to maintain a blood concentration of 150-250 ng/mL. CSA dosage was ending in complete withdrawal during the 9th month in patients without GVHD after HRD-HSCT. MMF was initiated orally at 500 mg/day on day +1, and withdrawn on day +100. MTX was given at 15 mg/m 2 on day +1 and at 10 mg/m 2 on days +3, +6, +11. All patients were hospitalized in a laminar airflow room and received prophylaxis for pneumocystis pneumonia with sulfamethoxazole, and anti-fungal prophylaxis with micafungin or voriconazole. Preemptive treatments were also administered for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation. All patients received antiemetic prophylaxis before daily TBI fraction with tropisetron hydrochloride injection.
High-resolution DNA typing for HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 were performed in all patients and donors. Patients and their donors were haploidentical. Donors were treated with rhG-CSF (Filgrastim, Kirin, Japan; 5 µg/kg/day) injected subcutaneously for 5-6 consecutive days, and peripheral blood stem cells (PBSCs) were collected on day 5 using a COBE Blood Cell Separator (Spectra LRS; COBE BCT Inc., Lakewood, CO, USA) from a total blood volume of 10-12 L. The target mononuclear cell (MNC) count and CD34 + cell count were 4 × 10 8 to 6 × 10 8 /kg and 3 × 10 6 to 4 × 10 6 /kg of recipient weight, respectively. If the target MNC count was not achieved, an additional harvest of PBSCs was performed on day 6. No graft was subjected to ex vivo T-cell depletion.
After allo-HSCT, bone marrow samples were analyzed at 1, 2, 3, 4, 5, 6, 9 and 12 months after transplantation and at 6-month interval thereafter to monitor minimal residual disease.
TBI using HT procedures
CT-simulation and contouring
Planning CT images (Siemens Biograph Sensation 16 PET/ CT, Siemens Medical Solutions Inc., Malvern, PA, USA 19355-1406) were acquired in the supine position with 5-mm slices. For contouring and planning, the Hi-Art treatment planning system (TPS) (Tomotherapy Inc., Madison, WI, USA 53717-1954) was used. For each patient, the lungs and lenses were outlined as organs at risk (OARs). The planning target volume (PTV) for each patient was defined as the whole body, excluding the OARs. The following organs were contoured for treatment planning: lungs, liver, spleen, heart, small and large bowel, kidneys, orbits, lenses, brain, esophagus, bladder, parotid glands, oral cavity, stomach, breasts, ovaries, major lymph node chains, and bone. The PTV of patients with body length exceeding 145 cm was divided into two parts and TBI was delivered in two successive sessions, head first from the vertex to the lower thigh (PTV1) and the remainder consisting of the lower extremities (PTV2).
TBI planning
Taking advantage of HT being able to deliver different radiation dose to very specific areas of the body at the same time, we create an optimal treatment plan to deliver 10 Gy to TBI and simultaneously augment 2 Gy dose (total dose of 12 Gy) to TMI and extramedullary disease sites (including CNS leukemia). TMI targets skeletal bone with active bone marrow sites such as the head (cranium and mandible), upper limb girdle (humerus, scapulae, clavicles), vertebrae (cervical, thoracic, lumbar and sacrum), lower limb girdle (os coxae and femoral head), and lower extremities to the tips of the feet. TBI and TMI was simultaneously performed in three equal fractions over 3 days, and with a minimum 12-h interfraction interval.
CT data sets with contours were transferred to the Hi-Art TPS (Tomotherapy Inc.) for planning. Constraints to be fulfilled were more than 80% of the PTV1 should be covered by the prescribed dose (10 Gy) and suppression of the lung dose to a mean dose (Dmean) of no more than 8 Gy and a minimum dose (Dmin) of 6 Gy. The PTV1 was generated by adding margins of 5 mm to thoracic bones, 1.5 cm to femur and shoulder bones, and 1 cm to all other bones. Plan parameters of TBI and TMI were set as follows: 5 cm for the field width, pitch of 0.43 or 0.287 and modulation factor ranging from 2.0 to 2.5.
Treatment delivery and quality assurance
Before HT treatment, all patients underwent four MV-CT scans in order to check their alignment. The first scan was carried out in the head/neck region and included the eyes and mandible, the second scan included part of the lung volume, the third scan included the kidneys and part of the pelvic region and the fourth scan included the knee area. Arc CHECK (Sunnuclear, FL, USA) was used for dose distribution verification encompassing either the brain or the lungs.
Statistical analysis
The present study is a prospective study. The sample size was calculated on the basis of expected disease-free survival (DFS) rate following allo-HSCT to our novel conditioning regimen using HT of 70% in patients with high-risk /refractory ALL and 35% of the null hypothesis rate referenced by the published studies evaluating agents for allo-HSCT therapy in high-risk/refractory ALL. We estimated that a sample size of 14 patients would give the study at least 80% power to reject the null hypothesis that DFS rate is not different from 35%, with a type I error level of 5% (two-sided).
The primary end-point was overall survival (OS). The secondary end points included DFS, the incidence of relapse, and non-relapse mortality (NRM). Acute and chronic GVHD, the incidence of serious, life-threatening, or fatal infection, incidence of CMV or EBV reactivation, NRM and relapse were described using cumulative incidence, with relapse as the competing event for TRM and death as the competing event for all other outcomes. OS and DFS were estimated using the Kaplan-Meier method.
Results
Patient, disease and transplantation characteristics
Fourteen patients with high-risk ALL or relapsed/refractory ALL who received HSCT from a haploidentical family donor at our center were included in this study. Table 1 shows the patient, disease and transplantation characteristics of the study patients. There were 11 males and 3 females. The median age of the patients was 22.5 years (range 12-50). Eight patients were classified as high risk at diagnosis including six patients with adverse cytogenetics (P006, P007, P009, P010, P012, P014), one patient with age >35 years (P004) and one B-ALL patient with high leukocyte counts >30 × 10 9 /L at diagnosis (P013). Three patients (P001, P005, P008) were primary induction failure. Three patients experienced late relapse after first complete remission (CR1), in which, Patient 003 achieved CR2, Patient 011 achieved partial remission (PR) and Patient 002 was refractory after salvage chemotherapy. The median time from diagnosis to HSCT was 6.1 months (range 3.8-87.5 months). At the time of transplantation, eight patients were in CR1, one patient in CR2, one patient in PR. Four patients had refractory disease at transplantation, in which, Patient 002 had only leukemic infiltration in bone marrow, Patient 008 had leukemic infiltration in bone marrow and persistent lymph node enlargement in the cervical, thoracic and celiac lymph nodes, and two patients (001, 005) achieved CR in bone marrow, but had persistent extramedullary leukemia from diagnosis to HSCT. Patients received stem cells from a direct family member, mother (n = 1), father (n = 5), brother (n = 3), sister (n = 4) or son (n = 1), who had more than three of ten HLA-A, HLA-B, HLA-C, HLA-DRB1 and DQ allele loci (>3/10) mismatched with the patient.
The endpoint of the last follow-up for all the surviving patients was August 31, 2016. The median follow-up for surviving patients was 14.6 months (range 4-28).
Characteristics and results of TBI by HT
Delivered average dose, dose homogeneity index (HI) and radiation conformal index (CI) of PTV1
Although major organs are included in PTV1, we describe the main characteristics of the PTV1. The median time of TBI total beam-on times was 102.9 min (range 75.8-137.4). The median delivered average dose was 11.395 Gy (range 
Fig. 1 A typical dose-volume histogram (DVH) for major normal organs and targeted dose boost to TMI by HT in one patient
Allo-HSCT using helical tomotherapy for ALL
Doses to OARs
Our results with HT TBI demonstrated satisfactory criticalorgan sparing without blocks of lung and kidney or reduced dose rates for lung and kidney protection. In all 14 patients, the median delivered doses to the left lung and right lung were 7.43 Gy (range 6.668-8.54) and 7.415 Gy (range 6.64-8.08), respectively. Renal toxicity due to TBI is also a serious problem in allo-HSCT and for other nephrotoxic therapy including chemotherapy, antifungals, and antibiotics. Kidney tolerance to fractionated TBI doses is 14 Gy in adults and <12 Gy in children [19, 20] . In our protocol, the median delivered doses to the left kidney and the right kidney were 11.01 Gy (range 9.75-12.52) and 11.135 Gy (range 9.64-12.13), respectively ( Table 3) . The planned targeted dose boost to TMI was 12 Gy. Although the median delivered dose to the ribs was 9.16 Gy (range 8.49-9.81) because of suppression of the lung dose, the median delivered dose to the major skeletal bones with active bone marrow sites was 12.685 Gy (range 11.12-13.52) ( Table 3) . A typical dose-volume histogram (DVH) for major normal organs and targeted dose boost to TMI from one patient treated with HT is shown in Fig. 1 . Table 1 ).
Dose HI of the OARs
Toxicity during TBI by HT
Adverse events (AEs) were evaluated according to NCI Common Terminology Criteria for AE (NCI-CTCAE), version 4.0. The most frequent extra-hematologic toxicities of TBI by HT were nausea and oral mucositis. All patients experienced nausea, which was grade 2 in eight patients and grade 3 in six patients. Oral mucositis was reported in 12 patients (85.7%), which was grade 2 in eight patients and grade 3 in four patients. Severe oral mucositis (grades 4 and 5) was not observed. Two patients experience grade 2 gastric hemorrhage. No patients experienced diarrhea that required intervention. No radiation dermatitis or radiation pneumonia was observed. No patient suffered severe acute toxicity during radiation. 
Transplant outcomes
GVHD and infection
Thirteen patients with myeloid engraftment and who survived at least 28 days were evaluable for the development of aGVHD, and the cumulative incidence of grades II-IV aGVHD at 3 months post-HSCT was 38.5% ± 0.3% (grade II = 3, grade IV = 2) (Fig. 2a) . One year after OS / DFS Fig. 2 Transplant outcomes. a the cumulative incidence of grades II-IV aGVHD. b the cumulative incidence of chronic GVHD. c one-year OS and DFS rates transplantation, the cumulative incidence of chronic GVHD was 25.4% ± 0.1% (Fig. 2b) . According to early virus reactivation (≤100 days), CMV viremia occurred in two patients and only one progressed to CMV retinitis after pre-emptive treatment. No EBV viremia was identified. Hemorrhagic cystitis occurred in four patients. In addition, one patient developed Pseudomonas aeruginosa septicemia and four patients experienced an invasive pulmonary fungal infection during the follow-up period, which met the criteria for probable or definite invasive fungal infection using standard criteria [21] .
Relapse, NRM, and survival after transplant
A total of four patients died after HSCT with a median time of 82.5 days (range , two patients died of severe infection (one with septicemia and one with pneumonia), one patient died of severe aGVHD and one patient died of an accident after hospital discharge.
With the exception of one patient who died before engraftment, at day +30 post HSCT, remaining 13 evaluable patients were alive and the CR rate was 100% (including three patients with extramedullary disease). As of August 31, 2016, no patient experienced recurrent disease after a median follow-up of 14.6 months (range 4-28). In six patients with adverse cytogenetics at diagnosis, two patients died without relapse and four patients achieved persistent complete cytogenetic response. Four patients with refractory disease at transplantation achieved persistent CR post-HSCT including remission of extramedullary leukemic infiltration. A typical comparison of CT images in Patient 008 with persistent leukemic infiltration in the cervical, above and below clavicle, axillary and thoracic lymph nodes pre-transplantation and the images posttransplantation are shown in supplementary Figure 1  ( sFig. 1) . One-year OS and DFS rates after transplantation were both 70.7% (Fig. 2c) .
Discussion
The past few years have seen growing improvement in HRD-HSCT. There are two major approaches to T-cellreplete HRD-HSCT used in bone marrow transplantation centers worldwide. The standard approach using post-HSCT high-dose cyclophosphamide for the selective depletion of alloreactive T cells in vivo achieved 7% of NRM, 11% of severe aGVHD, 64% of OS and 60% of DFS in patients with hematologic malignancies, which were equivalent to those of contemporaneous transplantation performed using matched sibling donors and unrelated donors [22] . Huang et al. at Peking University and other transplantation centers including us in China focused on T-replete HRD-HSCT by using ATG to achieve depletion of infused donor T lymphocytes in vivo. Published data suggested that the approach using ATG also could yield 60-79% of long-term OS in patients with acute leukemia with acceptable incidences of severe aGVHD (6-17.2%) and extensive cGVHD (12-14%) after HRD-HSCT [13, 17, 23] .
Conditioning plays a central role in allo-HSCT. A TBIcontaining conditioning regimen has been demonstrated to have distinct advantages over a non-TBI-containing regimen in terms of relapse rate, DFS and OS in patients with ALL [4, 24, 25] . However, the use of TBI has been associated with a variety of immediate and long-term posttransplant complications. Furthermore, in a conventional TBI delivery device, the entire clinical target volume is irradiated at the same time, and gains in disease control by escalation of TBI dose are associated with an increased TRM. Recently, for further dose escalation selective for the body sites harboring leukemic cells or with high risk for disease involvement, other investigators have explored the addition of linac-based targeted TMI or total marrow and lymphoid irradiation (TMLI) to a myeloablative chemotherapy-conditioning regimen before allo-HSCT [26, 27] . Compared with the standard fixed beam approach used by conventional TBI approach, HT employs a MV linear accelerator mounted on a CT gantry, which allows the beam source to continually rotate around the patient. This technique may be one potentially attractive technology to offer more accurate and conforming dose distributions to large complex target shapes due to 360°of beam application [9, 11, 12, 28] . HT is able to show the difference of delivered dose and the planned dose minutely and significantly reduced the dosimetric verification time by comparison of the reconstructed dose with the planned dose in 3-D on the basis of DVH, region of Interest statistics and viewed dose distribution superimposed on CT axial cuts [28] .
To our knowledge, the present study is the first clinical trial to use HT for TBI and concomitant dose escalation to bone marrow and extramedullary disease sites in patients with high-risk and refractory ALL undergoing allo-HSCT. The results of our trial suggest that there are three attractive aspects of using HT for TBI in the setting of allo-HSCT. First, TBI using HT confers satisfactory immunosuppression in haploidentical HSCT. Although the recent decade has witnessed significant advances in haploidentical HSCT, this technique may be complicated by high rates of graft rejection, GVHD, and TRM [29] . All our evaluable patients achieved sustained, full donor stem cell engraftment by day 30 after HSCT. The cumulative incidence of grades II-IV aGVHD at 3 months post-HSCT was 38.5 ± 0.3%, which is comparable to the incidence reported in published studies of myeloablative T-replete haploidentical HSCT either using conventional Linac-based TBI [22] or non-TBI containing conditioning [13, 30] .
Second, TBI using HT has an excellent effect on the eradication of malignant cells in patients with high-risk ALL undergoing allo-HSCT, especially those with refractory ALL. The superior effect of HT may be attributable to several factors, such as homogeneous dose distributions, selective boost modality to bone marrow, the area of greatest leukemic burden, and individualized dose escalation to extramedullary leukemic sites on the basis of the patient's previous disease history. To date, only two trials have reported the clinical utility of using HT to deliver TBI in allo-HSCT. Peñagarícano et al. presented the clinical feasibility of HT for TBI as part of a preparatory regimen before allo-SCT in four patients with acute myeloid leukemia (AML). Their results showed that two patients are alive with no evidence of disease relapse and two patients died of GVHD, but there was no evidence of disease relapse at the time of death. They concluded that HT simplifies the process of TBI and dose verification is possible with HT showing small differences between planned and delivered doses [28] . Gruen et al. established TBI using HT in ten patients with high-risk ALL or AML receiving allo-HSCT, in which six patients had recurrent disease. During 1-15 months of follow-up post-HSCT, two patients experienced NRM, and the remaining eight patients achieved stable remission without further radiation-related morbidity [31] .
In addition, there are some published studies evaluated the role and feasibility of HT in targeted TMI or TMLI in auto-HSCT or allo-HSCT. Wong JY's study of three patients suggested that this more targeted approach with DVH analysis predicted the potential to escalate the doseto-bone (containing marrow) up to 20 Gy, while maintaining doses to normal organs at lower levels than in conventional TBI to 12 Gy [11] . Stein A, et al. recently also conducted a phase I trial for TMLI in 51 patients with relapsed/refractory acute leukemia undergoing allo-HSCT. Their results indicated that TMLI is safe up to a total dose of 20 Gy and radiation to off-target critical organs is lower than typically delivered by TBI [32] . Wong JY et al. further carried out an autologous HSCT trial in 13 patients with multiple myeloma (MM) with high dose melphalan, followed 6 weeks later by TMI to skeletal bone using HT, and a separate allo-HSCT trial in eight patients (5 AML, 1 ALL, 1 NHL, 1 MM) treated with TMLI + splenic irradiation to 12 Gy using HT combined with fludarabine/melphalan. Their results demonstrated that TMI or TMLI using HT is clinically feasible and the observed decrease in acute toxicities compared favorably with those seen with standard TBI [12] . Corvo R et al. reported their clinical experience in planning and delivering TMI using HT after conventional TBI in 15 patients with relapsed acute leukemia undergoing allo-HSCT, in which 8 patients were in relapse and 7 in second or third CR after relapse. Their results showed that all patients treated with TBI/TMI achieved CR after SCT and 12 patients are alive with 10 survivors in clinical remission, which suggested that for patients with advanced leukemia, targeted TMI using HT after conventional TBI may be a novel approach to increase radiation dose with a low risk of severe toxicity [10] .
Based on this rationale, we established a novel approach of using HT simultaneously for TBI and dose escalation to bone marrow and extramedullary disease sites as a conditioning regimen for patients with high-risk or relapsed/ refractory ALL receiving haploidentical HSCT. Our 14 patients received a median PTV1 D95 of 8.2 Gy (range 7.52-9.01) with the median targeted dose escalation to TMI of 12.685 Gy (range 11.12-13.52). After a median followup of 14.6 months (range 4-28), four patients experienced NRM, ten patients are alive in stable CR, and four of these patients with refractory disease at transplantation achieved persistent CR post-HSCT including remission of extramedullary leukemic infiltration. Recent data suggested that the incidence of DFS in adult patients with high-risk ALL receiving allo-HSCT in CR1 was around 60% [17, 33, 34] . Although allo-HSCT is the only curative option for relapsed or refractory adult ALL, outcomes remain poor and reported rates of DFS after allo-HSCT for patients in CR2 or with advanced disease range from 17-35% [34, 35] . According to pediatric ALL patients receiving allo-HSCT, the rates of DFS were around 62-64% in patients with very high-risk ALL in CR1, 59% in induction faiure [1, 36, 37] . Our protocol yielded satisfactory outcomes for high-risk and refractory ALL with one-year OS and DFS rates after transplantation of 70.7%.
Third, due to individual sparing of organs at high risk of radiation-induced toxicity, TBI using HT is well tolerated with acceptable associated toxicities. In conventional TBI, even when fractionated and low-dose-rate TBI is employed with concurrent chemotherapy, the rate of interstitial pneumonitis may approach 25% [9] . Zhuang AH et al. compared HT for delivering TBI with conventional extended source-to-surface distance technique in four patients. Their results suggested that HT-based TBI plans have better dose coverage to the target and better dose sparing to the lungs compared with the conventional extended source-tosurface distance (X-SSD) technique, which applies dose compensators, lung blocks, and electron boosts [38] . Wong JY et al. further demonstrated a 1.7-7.5-fold reduction in median organ dose with HT compared with conventional TBI [11] . In the present study, the median delivered doses to the left lung, right lung, left kidney and right kidney were no more than the tolerance suppression. No radiation dermatitis or radiation pneumonia was observed. On the other hand, due to the choice of treatment parameters, small organs located in the head region such as the parotid glands and oral mucosa were less spared than others, as we observed that 85.7% of patients had oral mucositis with grade 2 in eight patients and grade 3 in four patients, which is comparable to other experiences with HT [39, 40] .
In conclusion, our data provide preliminary data to illustrate the feasibility of using HT for TBI and concomitant targeted boost to specific body sites with higher tumor burden, such as bone marrow, sanctuary organs such as testes or brain and extramedullary leukemic sites as part of the conditioning regimen in allo-HSCT, especially in high-risk or refractory ALL patients. We must acknowledge some limitations of our study including a single center study of the small number of patients, with short follow-up period and the lack of control group involving conventional linacbased TBI. Although we estimated that 14 patients would be needed for the statistical analysis to be meaningful. No patient was dropped out after inclusion and all 14 patients received a transplant. Four patients died of TRM in our study and we should include more patients as far as possible to strengthen the statistical power. Further evaluation is also needed to better characterize long-term toxicities and to assess the optimal tolerated dose of TBI and TMI in a large number of patients.
